Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Two years ago, Eisai Inc. restructured its R&D operations to create small, venture-like units to be both time- and cost-effective. Now the company is touting the plan's success, having shaved months off of many of its drug development timelines. The company recently filed approval submissions for first-in-class AMPA receptor antagonist perampanel more than a year ahead of schedule
You may also be interested in...
Eisai Manufacturing Changes Again, With Biogen Idec In The Mix
Eisai and Biogen Idec formed a manufacturing alliance for oral solids and parenteral capabilities, as Eisai continues to tinker with its global manufacturing model. Eisai also takes a new approach to academic partnerships with University College London for neurological targets.
Islands Dispute Hits Japan Device Sales In China While Pharma Less Affected
Both Japanese and Chinese device makers have reported lower sales and profits linked to a rift over disputed islands, potentially signaling a lengthy period of strained trade ties.
Eisai, Morphotek Gain Biologics Manufacturing Capability With New Plant Opening
Eisai gains biologics capability from subsidiary Morphotek’s new biologics manufacturing plant, as Eisai ramps up in emerging markets and transitions itself in a post-Aricept patent world.